Gene Therapy Progress and Prospects: cancer gene therapy using tumour suppressor genes (original) (raw)
Rosenwald A et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947. ArticlePubMed Google Scholar
Khan J et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001; 7: 673–679. ArticleCASPubMedPubMed Central Google Scholar
Buller RE et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553–566. ArticleCASPubMed Google Scholar
Schuler M et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750–1758. ArticleCASPubMed Google Scholar
Kuball J et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002; 20: 957–965. ArticleCASPubMed Google Scholar
Pagliaro LC et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003; 21: 2247–2253. ArticleCASPubMed Google Scholar
Lang FF et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21: 2508–2518. ArticleCASPubMed Google Scholar
Zeimet AG, Marth C . Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003; 4: 415–422. ArticleCASPubMed Google Scholar
Reles A et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984–2997. CASPubMed Google Scholar
Vousden KH, Lu X . Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594–604. ArticleCASPubMed Google Scholar
Wolf BB et al. Defective cytochrome _c_-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem 2001; 276: 34244–34251. ArticleCASPubMed Google Scholar
de Vries A et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 2002; 99: 2948–2953. ArticleCASPubMedPubMed Central Google Scholar
Bergamaschi D et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3: 387–402. ArticleCASPubMed Google Scholar
Reid T et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy 2001; 8: 1618–1626. ArticleCASPubMedPubMed Central Google Scholar
Hamid O et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498–1504. ArticleCASPubMed Google Scholar
Vasey PA et al. Phase I trial of intraperitoneal injection of the E1B-55-kDa-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562–1569. CASPubMed Google Scholar
Hecht JR et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555–561. CASPubMed Google Scholar
Mulvihill S et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy 2001; 8: 308–315. ArticleCASPubMed Google Scholar
Reid T et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070–6079. CASPubMed Google Scholar
Dix BR et al. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol 2001; 75: 5443–5447. ArticleCASPubMedPubMed Central Google Scholar
Ries SJ et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 2000; 6: 1128–1133. ArticleCASPubMed Google Scholar
Edwards SJ et al. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol 2002; 76: 12483–12490. ArticleCASPubMedPubMed Central Google Scholar
Flesken-Nikitin A et al. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003; 63: 3459–3463. CASPubMed Google Scholar
Ip SM et al. pRb-expressing adenovirus Ad5-Rb attenuates the p53-induced apoptosis in cervical cancer cell lines. Eur J Cancer 2001; 37: 2475–2483. ArticleCASPubMed Google Scholar
Li D et al. The role of adenovirus-mediated retinoblastoma 94 in the treatment of head and neck cancer. Cancer Res 2002; 62: 4637–4644. CASPubMed Google Scholar
Zhang X et al. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res 2003; 63: 760–765. CASPubMed Google Scholar
Wills KN et al. Tissue-specific expression of an anti-proliferative hybrid transgene from the human smooth muscle alpha-actin promoter suppresses smooth muscle cell proliferation and neointima formation. Gene Therapy 2001; 8: 1847–1854. ArticleCASPubMed Google Scholar
Claudio PP et al. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus- mediated gene transfer. Cancer Res 2000; 60: 372–382. CASPubMed Google Scholar
Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134–1139. ArticleCASPubMed Google Scholar
Fueyo J et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2–12. ArticleCASPubMed Google Scholar
Bauerschmitz GJ et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266–1270. CASPubMed Google Scholar
Fueyo J et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652–660. ArticleCASPubMed Google Scholar
Jakubczak JL et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003; 63: 1490–1499. CASPubMed Google Scholar
Johnson L et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1: 325–337. ArticleCASPubMed Google Scholar
Branton PE, Roopchand DE . The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene 2001; 20: 7855–7865. ArticleCASPubMed Google Scholar
Sharpless NE et al. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 2003; 22: 5055–5059. ArticleCASPubMed Google Scholar
Modesitt SC et al. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res 2001; 7: 1765–1772. CASPubMed Google Scholar
Turturro F et al. Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease. Leukemia Lymphoma 2002; 43: 1323–1328. ArticleCASPubMed Google Scholar
Simon M et al. Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression. J Neurooncol 2002; 60: 1–12. ArticlePubMed Google Scholar
Kawakami Y et al. Adenovirus-mediated p16 gene transfer changes the sensitivity to taxanes and Vinca alkaloids of human ovarian cancer cells. Anticancer Res 2001; 21: 2537–2545. CASPubMed Google Scholar
Hemmati PG et al. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene 2002; 21: 3149–3161. ArticleCASPubMed Google Scholar
Kuo ML et al. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 2003; 63: 1046–1053. CASPubMed Google Scholar
Lu W et al. Expression of p14ARF overcomes tumor resistance to p53. Cancer Res 2002; 62: 1305–1310. CASPubMed Google Scholar
Saadatmandi N et al. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status. Cancer Gene Ther 2002; 9: 830–839. ArticleCASPubMed Google Scholar
Tango Y et al. Adenovirus-mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells. Hum Gene Ther 2002; 13: 1373–1382. ArticleCASPubMed Google Scholar
Yang CT et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000; 92: 636–641. ArticleCASPubMed Google Scholar
Deng X et al. Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin. Biochem Biophys Res Commun 2002; 296: 792–798. ArticleCASPubMed Google Scholar
Weber HO et al. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 2002; 21: 3207–3212. ArticleCASPubMed Google Scholar
Eymin B et al. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20: 1033–1041. ArticleCASPubMed Google Scholar
Fatyol K, Szalay AA . The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha ) and inhibits HIF-1-mediated transcription. J Biol Chem 2001; 276: 28421–28429. ArticleCASPubMed Google Scholar
Karayan L et al. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 2001; 20: 836–848. ArticleCASPubMed Google Scholar
Eymin B et al. p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 2003; 22: 1822–1835. ArticleCASPubMed Google Scholar
Stahl JM et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003; 63: 2881–2890. CASPubMed Google Scholar
Fernandez M, Eng C . The expanding role of PTEN in neoplasia: a molecule for all seasons? Clin Cancer Res 2002; 8: 1695–1698. CASPubMed Google Scholar
Huang H et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 2001; 276: 38830–38836. ArticleCASPubMed Google Scholar
Yuan XJ, Whang YE . PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002; 21: 319–327. ArticleCASPubMed Google Scholar
Davies MA et al. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 2002; 8: 1904–1914. CASPubMed Google Scholar
Tanaka M, Grossman HB . In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Therapy 2003; 10: 1636–1642. ArticleCASPubMed Google Scholar
Huang J, Kontos CD . PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 2002; 277: 10760–10766. ArticleCASPubMed Google Scholar
Abe T et al. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res 2003; 63: 2300–2305. CASPubMed Google Scholar
Ekmekcioglu S et al. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer 2001; 94: 54–59. ArticleCASPubMed Google Scholar
Saeki T et al. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Ther 2000; 7: 2051–2057. ArticleCASPubMed Google Scholar
Mhashilkar AM et al. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol Med 2001; 7: 271–282. ArticleCASPubMedPubMed Central Google Scholar
Saeki T et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 2002; 21: 4558–4566. ArticleCASPubMed Google Scholar
Pataer A et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 2002; 62: 2239–2243. CASPubMed Google Scholar
Mhashilkar AM et al. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther 2003; 8: 207–219. ArticleCASPubMed Google Scholar
Ramesh R et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res 2003; 63: 5105–5113. CASPubMed Google Scholar
Sellar GC et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003; 34: 337–343. ArticleCASPubMed Google Scholar